UNSPSC 51312502: Clobenzepam

This classification denotes a histamine-1 receptor antagonist with the molecular formula C17H18ClN3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0O6W0NP518, chemically known as 10,11-dihydro-11-oxo-5h-dibenzo(b,e)(1,4)diazepine, 7-chloro-10-(2-(dimethylamino)ethyl)- but generally known as clobenzepam, which bears US NIH Compound Identifier 14396. European Medicines Agency schedules Clobenzepam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06675MIG.

UNSPSC 51312502 Clobenzepam is a Commodity code tracking pharmaceutical products, but recent state and local solicitation activity shows minimal direct procurement of the substance itself. Instead, issuing bodies are buying pharmaceutical distribution services, naloxone supply chains, generic multi-source medications through cooperative purchasing, and exploratory contracting for direct-to-manufacturer prescription programs. The actual purchasing activity under this code taxonomy spans health departments, cooperative alliances, and state health and human services commissions seeking to establish vendor relationships for drug supply, fulfillment logistics, and pharmacy benefit management rather than ordering clobenzepam as a line item.

Recent opportunities reflect three issuing bodies across Florida, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive bidding, with a response deadline of July 26, 2023, for quarterly delivery to the Seminole County Community Health Building in Sanford. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, exploring how state agencies can contract directly with pharmaceutical manufacturers outside traditional pharmacy benefit manager arrangements. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products distributed across state and local government facilities in Minnesota and Oregon, with proposals due March 26, 2026 and contract awards effective July 1, 2026 through authorized wholesalers including AmerisourceBergen, Cardinal Health, and Morris & Dickson. Activity concentrates in the upper Midwest and Southeast, with cooperative purchasing vehicles and health agency procurement dominating the recent solicitation landscape.